Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Big Is The Neurogenetic Testing Market Today And What Is Its Future Size?

Recent years have witnessed swift expansion in the neurogenetic testing market. From $0.61 billion in 2024, it is projected to reach $0.7 billion in 2025, exemplifying a compound annual growth rate (CAGR) of 13.5%. This significant surge during the historic period can be associated with the escalating instances of neurological diseases, expanded research in the field of life science, rising occurrence of Parkinson’s disease, a surge in cancer cases, and a growing consciousness among healthcare professionals.

The market size of neurogenetic testing is projected to experience a significant expansion in the coming years, reaching $1.12 billion in 2029 with a 12.7% compound annual growth rate (CAGR). This growth during the forecast period can be linked to the burgeoning use of personalized medicine, the escalating incidence of chronic diseases, the growing quantity of hospitals and diagnostic laboratories, and the increasing demand for the early detection of diseases. Key trends during this forecast period involve technological advancement, heightened acceptance of non-invasive testing methods, the introduction of new products, strategic partnerships, and the appearance of innovative biomarkers for neurological disorders.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

Which Demand Drivers Are Strengthening The Neurogenetic Testing Market?

The increasing incidence of neurological disorders is anticipated to boost the neurogenetic testing market’s expansion. Neurological disorders encompass a range of conditions that impact the nervous system, comprising the brain, spinal cord, and nerves. These disorders are often attributed to genetic susceptibility, infections, trauma, toxins, autoimmune reactions, and degeneration. Neurogenetic testing plays a pivotal role in the diagnosis, treatment, and management of these disorders by providing personalized genetic risk factor insights. This not only helps in making treatment decisions but also empowers patients and their families to make knowledgeable healthcare choices, thereby enhancing patient care and outcomes. As an example, the European Brain Council, a non-profit organization based in Belgium, stated in April 2022 that approximately 600 neurological diseases and nearly 300 psychiatric conditions affected millions worldwide, including 65 million individuals with epilepsy. In Europe, there are 10.5 million people living with dementia, a figure projected to increase to 18.7 million by 2050. Consequently, the increasing prevalence of neurological disorders is likely to spur the growth of the neurogenetic testing market.

Which Segment Accounts For The Largest Share In The Neurogenetic Testing Market?

The neurogenetic testingmarket covered in this report is segmented –

1) By Type: Microarray Analysis; Whole-Exome Sequencing (WES); Multiplex Ligation Dependent Probe Amplification (MLPA); Polymerase Chain Reaction (PCR) Tests; Other Types

2) By Disease: Rare Genetic Disorder; Cancer; Cystic Fibrosis; Sickle Cell Anemia; Duchenne Muscular Dystrophy; Thalassemia; Huntington’s Disease; Fragile X Syndrome; Other Diseases

3) By End-Users: Hospitals; Specialty Clinics; Research Institutes; Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray; Single Nucleotide Polymorphism (SNP) Microarray; Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing; Clinical Exome Sequencing; Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation; MLPA For Methylation Analysis; MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR); Reverse Transcription PCR (RT-PCR); Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS); Southern Blotting; Fluorescence In Situ Hybridization (FISH); Sanger Sequencing

Which Long-Term Trends Will Play A Crucial Role In The Neurogenetic Testing Market?

Key players in the neurogenetic testing market are introducing trailblazing products like whole-genome sequencing to increase the precision and reach of genetic examination, thus facilitating comprehensive and personalized tests for neurological conditions. Whole-genome sequencing (WGS) is an exhaustive method of genetic testing, as it determines the complete DNA sequence of a person’s entire genome. For instance, in March 2024, Nucleus Genomics, a US-based genetics analysis company, unveiled a DNA analysis product. This platform gives people insight into their genetic makeup, aiding them in making knowledgeable choices about their health and wellness. With pioneering technology and superb genetic counseling services, Nucleus Genomics is positioned to transform the genetic testing industry, making whole-genome sequencing directly accessible to individuals, and heralding a new era in genomic medicine.

Which Companies Hold A Competitive Edge In The 1053 Market?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Which Region Is Forecasted To Lead The Neurogenetic Testing Market In The Coming Years?

North America was the largest region in the neurogenetic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp

Browse Through More Reports Similar to the Global Neurogenetic Testing Market 2025, By The Business Research Company

Genetic Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Epigenetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/epigenetics-global-market-report

Optogenetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/optogenetics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model